BRIEF published on 09/04/2024 at 17:50, 2 years ago Median Technologies: Promising results for the diagnosis of lung cancer Artificial Intelligence Median Technologies Lung Cancer Eyonis™ LCS Pivotal Study
PRESS RELEASE published on 09/04/2024 at 17:45, 2 years ago Informations privilégiées / Autres communiqués Median Technologies partagera les résultats de eyonis™ LCS au WCLC 2024, montrant une précision sans précédent dans le diagnostic précoce du cancer du poumon Median Technologies Cancer Du Poumon Eyonis™ LCS WCLC 2024 Diagnostic Précoce
PRESS RELEASE published on 09/04/2024 at 17:45, 2 years ago Inside Information / Other news releases Median Technologies to share positive pivotal data for eyonis™ LCS diagnostic software at IASLC 2024 World Conference on Lung Cancer. eyonis™ LCS achieves high accuracy in detecting lung cancer Median Technologies Lung Cancer Eyonis LCS IASLC 2024 Diagnostic Software
BRIEF published on 08/29/2024 at 17:50, 2 years ago Median Technologies : eyonis atteint les objectifs de l'étude REALITY Dépistage Median Technologies Cancer Du Poumon Eyonis™ LCS AUC
BRIEF published on 08/29/2024 at 17:50, 2 years ago Median Technologies: eyonis achieves REALITY study objectives Screening Median Technologies Lung Cancer Eyonis™ LCS AUC
PRESS RELEASE published on 08/29/2024 at 17:45, 2 years ago Informations privilégiées / Autres communiqués Median Technologies annonce que l'étude pivot REALITY évaluant eyonis™ LCS dans le dépistage du cancer du poumon répond à tous les critères d'évaluation primaire et secondaires Dépistage Median Technologies Cancer Du Poumon Eyonis LCS Étude Pivot
BRIEF published on 07/18/2024 at 18:01, 2 years 1 month ago Median Technologies dévoile des résultats semestriels et des avancées stratégiques Chiffre D'affaires Intelligence Artificielle Carnet De Commandes ICRO Eyonis™ LCS
BRIEF published on 07/18/2024 at 18:01, 2 years 1 month ago Median Technologies unveils half-year results and strategic advances Artificial Intelligence Turnover Backlog ICRO Eyonis™ LCS
PRESS RELEASE published on 07/18/2024 at 17:56, 2 years 1 month ago Informations privilégiées / Communiqué sur comptes, résultats Median Technologies annonce un carnet de commandes record et les résultats de l'étude eyonis LCS. Chiffre d'affaires semestriel à 10,9 m€, vision et opportunités de croissance en iCRO. Webcast avec le CEO le 24/07/2024 Chiffre D'affaires Carnet De Commandes Median Technologies ICRO Eyonis LCS
PRESS RELEASE published on 07/18/2024 at 17:56, 2 years 1 month ago Inside Information / News release on accounts, results Median Technologies reports record iCRO backlog and eyonis™ LCS on-track for pivotal study readout in August. Revenue at €10.9 million, cash at €16 million. CEO to provide update via webcast on July 24, 2024 Revenue Growth Median Technologies ICRO Eyonis LCS Pivotal Study
Published on 09/12/2026 at 02:35, 1 day 4 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 8 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 9 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 14 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 13 hours 32 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 23 hours 52 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 9 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 9 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 11 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 2 days ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 2 days 11 hours ago Availability of the 2026 Interim Financial Report
